CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK) from its SEC filings: 2025 revenue $88.0 million (+377% vs the year before), net margin -892%, free cash flow -$534.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $88.0 million |
| Revenue growth | +377% |
| Net income | -$785.0 million |
| Net margin | -891.6% |
| Free cash flow | -$534.8 million |
| Diluted EPS | $-6.54 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -57% |
| Cash | $255.3 million |
| Long-term debt | $248.2 million |
| Share count, 1 year | +16% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.